51656-90-7

Basic information

• Product Name: 8-METHYLENE-1,4-DIOXA-SPIRO[4.5]DECANE
• Synonyms: 8-METHYLENE-1,4-DIOXA-SPIRO[4.5]DECANE;1,4-Dioxaspiro[4.5]decane, 8-methylene-
• CAS NO: 51656-90-7
• Molecular Formula: C₉H₁₄O₂
• Molecular Weight: 154.21
• Product Categories: Miscellaneous
• Mol File: 51656-90-7.mol
• Article Data: 48

Chemical Properties

• Boiling Point: 221.4±40.0 °C(Predicted)
• Appearance: /
• Density: 1.04±0.1 g/cm3(Predicted)
• CAS DataBase Reference: 8-METHYLENE-1,4-DIOXA-SPIRO[4.5]DECANE(CAS DataBase Reference)
• NIST Chemistry Reference: 8-METHYLENE-1,4-DIOXA-SPIRO[4.5]DECANE(51656-90-7)
• EPA Substance Registry System: 8-METHYLENE-1,4-DIOXA-SPIRO[4.5]DECANE(51656-90-7)

Safety Data

• Hazardous Substances Data: 51656-90-7(Hazardous Substances Data)

Usage

General Description

8-Methylene-1,4-dioxa-spiro[4.5]decane is a chemical compound with a spiro ring structure consisting of a six-membered and a seven-membered ring fused together. It is used in the synthesis of various organic compounds and has potential applications as a building block for pharmaceuticals and agrochemicals. 8-METHYLENE-1,4-DIOXA-SPIRO[4.5]DECANE may also be used in chemical research and development, as well as in the production of specialty chemicals. It should be handled and stored with care, as it may pose hazards if not properly managed.

Upstream product

• 4746-97-8 cyclohexanedione monoethylene ketal 
• 27200-84-6 methyl triphenylphosphonium bromide 
• 2065-66-9 methyl-triphenylphosphonium iodide 
• 183-97-1 1,4,9,12-Tetraoxa-dispiro[4.2.4.2]tetradecane 
• 873869-19-3 1-(tert-butyl)-5-(methylsulfonyl)-1H-tetrazole 
• 4210-04-2 3,5-bis(trifluoromethyl)phenyl methyl sulfone 
• 1779-49-3 Methyltriphenylphosphonium bromide 
• 19493-09-5 Methylenetriphenylphosphorane 

Downstream Products

• 23521-81-5 (1,4-dioxaspiro[4.5]dec-8-yl)methanol 
• 93245-98-8 1,4-dioxaspiro[4.5]decane-8-carbaldehyde 
• 52875-47-5 7,10-dioxadispiro[2.2.4⁶.2³]dodecane 
• 33082-72-3 4-methyl-3-cyclohexen-1-one ethylene ketal 
• 1440962-12-8 8,11-dioxadispiro[3.2.4⁷.2⁴]tridecan-2-one 
• 99799-73-2 spiro[2.5]octane-6-amine 
• 134136-04-2 (1,4-dioxa-spiro[4.5]-dec-8-yl)-acetic acid 
• 1256545-97-7 (8-fluoro-1,4-dioxaspiro[4.5]decan-8-yl)methanol 
• 4746-97-8 cyclohexanedione monoethylene ketal 

Relevant articles and documents

Stereoselective Diboration of Spirocyclobutenes: A Platform for the Synthesis of Spirocycles with Orthogonal Exit Vectors

The diastereo- and enantioselective diboration of spirocyclobutenes provides a platform for the rapid preparation of a wide variety of chiral spirocyclic building blocks. The chemoselective functionalization of the carbon-boron bond in the products, including a stereospecific sp3-sp2 Suzuki–Miyaura cross-coupling reaction, provides a powerful tool to control the directionality and the nature of the exit vectors in the spirocyclic framework.

PYRIDAZINONE DERIVATIVE

Provided are: a pyridazinone derivative and/or a pharmaceutically acceptable salt thereof, which is useful as a therapeutic agent and/or a prophylactic agent for diseases in which Nav1.1 is involved and various central nervous system diseases; and a medicine containing the pyridazinone derivative and/or the pharmaceutically acceptable salt thereof as an active ingredient. A compound represented by formula (1) or a pharmaceutically acceptable salt thereof. [In the formula, M1 represents a saturated or partially unsaturated C4-12 carbocyclic group or the like; R1 and R2 independently represent a hydrogen atom or the like; M2 represents a group represented by formula (2a) or the like; X1a, X1b and X1c independently represent N or the like; X2, X3 and X4 independently represent CR3 or the like; A1 and A2 independently represent N or the like; and R3 represents a hydrogen atom or the like.]

N-(PYRIDIN-2-YLSULFONYL)CYCLOPROPANECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF A CFTR MEDIATED DISEASE

The invention relates to heterocyclic compounds of the formula (I), in which all of the variables are as defined in the specification; capable of modulating the activity of CFTR. The invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, in particular to their use in the treatment and management of diseases or disorders including Cystic fibrosis and related disorders.